Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
netFormulary
Home
Treatment Use
Class
Chapters
News
Reports
Contact
SEARCH
Searching for :
Daratumumab
Open monograph to display formulary status.
Formulary items found
Status
Description
Section
RED
Daratumumab 20mg/mL Darzalex
®
(Concentrate for infusion)
Malignant disease and immunosuppression, Other antineoplastic drugs, 08.01.05
Links found
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (replaced by NICE TA897)
NICE TA763 Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable
NICE TA783: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
NICE TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
NICE TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
NICE TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis